c-erbB-2 oncogene as a prognostic marker in breast cancer.

Por Perren, T. J.
Publicado em 1991

Adjuvant therapy for operable breast cancer; more answers, new questions.

Por Perren, T. J.
Publicado em 1995

The Cytotoxics Handbook

Por Perren, T.J.
Publicado em 1991

Recent EORTC and MRC UK studies: implications for imaging ovarian cancer

Por Spencer, John A., Perren, Timothy J.
Publicado em 2010

The selective carotid arterial vasoconstrictor action of GR43175 in anaesthetized dogs.

Por Feniuk, W., Humphrey, P. P., Perren, M. J.
Publicado em 1989

Vascular 5-HT1-like receptors that mediate contraction of the dog isolated saphenous vein and carotid arterial vasoconstriction in anaesthetized dogs are not of the 5-HT1A or 5-HT1...

Por Perren, M. J., Feniuk, W., Humphrey, P. P.
Publicado em 1991

A comparison of 5-hydroxytryptamine receptors mediating contraction in rabbit aorta and dog saphenous vein: evidence for different receptor types obtained by use of selective agoni...

Por Feniuk, W., Humphrey, P. P., Perren, M. J., Watts, A. D.
Publicado em 1985

5-Carboxamidotryptamine is a selective agonist at 5-hydroxytryptamine receptors mediating vasodilatation and tachycardia in anaesthetized cats.

Por Connor, H. E., Feniuk, W., Humphrey, P. P., Perren, M. J.
Publicado em 1986

Etoposide and adriamycin containing combination chemotherapy (HOPE-Bleo) for relapsed Hodgkin's disease.

Por Perren, T. J., Selby, P. J., Milan, S., Meldrum, M., McElwain, T. J.
Publicado em 1990

Chemotherapy for malignant melanoma: combinations and high doses produce more responses without survival benefit.

Por Lakhani, S., Selby, P., Bliss, J. M., Perren, T. J., Gore, M. E., McElwain, T. J.
Publicado em 1990

Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies.

Por Banks, R. E., Gearing, A. J., Hemingway, I. K., Norfolk, D. R., Perren, T. J., Selby, P. J.
Publicado em 1993

High dose melphalan, BCNU and etoposide with autologous bone marrow transplantation for Hodgkin's disease.

Por Zulian, G. B., Selby, P., Milan, S., Nandi, A., Gore, M., Forgeson, G., Perren, T. J., McElwain, T. J.
Publicado em 1989

Phase II study of docetaxel in combination with epirubicin and protracted venous infusion 5-fluorouracil (ETF) in patients with recurrent or metastatic breast cancer. A Yorkshire b...

Por Humphreys, A C, Dent, J, Rodwell, S, Crawford, S M, Joffe, J K, Bradley, C, Dodwell, D, Perren, T J
Publicado em 2004

The use of tumour markers CEA, CA-195 and CA-242 in evaluating the response to chemotherapy in patients with advanced colorectal cancer.

Por Ward, U., Primrose, J. N., Finan, P. J., Perren, T. J., Selby, P., Purves, D. A., Cooper, E. H.
Publicado em 1993

A phase II study of recombinant interferon-beta (r-hIFN-beta 1a) in combination with 5-fluorouracil (5-FU) in the treatment of patients with advanced colorectal carcinoma.

Por Joffe, J. K., Perren, T. J., Bradley, C., Primrose, J., Hallam, S., Ward, U., Illingworth, J. M., Selby, P. J.
Publicado em 1997

Timing of breast cancer surgery in relation to menstrual cycle phase: no effect on 3-year prognosis: The ITS Study

Por Thorpe, H, Brown, S R, Sainsbury, J R, Perren, T J, Hiley, V, Dowsett, M, Nejim, A, Brown, J M
Publicado em 2008

Cytogenetic alterations in ovarian clear cell carcinoma detected by comparative genomic hybridisation

Por Dent, J, Hall, G D, Wilkinson, N, Perren, T J, Richmond, I, Markham, A F, Murphy, H, Bell, S M
Publicado em 2003

GR43175, a selective agonist for the 5-HT1-like receptor in dog isolated saphenous vein.

Por Humphrey, P. P., Feniuk, W., Perren, M. J., Connor, H. E., Oxford, A. W., Coates, L. H., Butina, D.
Publicado em 1988

A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. The London Gynaecologic Oncology Group.

Por Perren, T. J., Wiltshaw, E., Harper, P., Slevin, M., Stein, R., Tan, S., Gore, M., Fryatt, I. J., Blake, P. R.
Publicado em 1993

The prophylactic role of intravenous and long-term oral acyclovir after allogeneic bone marrow transplantation.

Por Selby, P. J., Powles, R. L., Easton, D., Perren, T. J., Stolle, K., Jameson, B., Fiddian, A. P., Tryhorn, Y., Stern, H.
Publicado em 1989